US FDA's new leaders to focus on restoring credibility and improving transparency
This article was originally published in Scrip
Executive Summary
Improving the US FDA's credibility will be a major focus of the agency's new leadership, principal deputy commissioner Dr Joshua Sharfstein told a congressional panel on May 21st.